Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Current Deferred Revenue for 6 consecutive years, with $1.3 million as the latest value for Q2 2023.

  • Quarterly Current Deferred Revenue changed N/A to $1.3 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Jun 2023, changed N/A year-over-year, with the annual reading at $290.1 million for FY2022, 939.06% up from the prior year.
  • Current Deferred Revenue for Q2 2023 was $1.3 million at Denali Therapeutics, down from $1.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $290.1 million in Q4 2022, with the low at $23000.0 in Q3 2022.
  • Average Current Deferred Revenue over 5 years is $33.1 million, with a median of $19.3 million recorded in 2019.
  • Peak annual rise in Current Deferred Revenue hit 939.06% in 2022, while the deepest fall reached 98.26% in 2022.
  • Over 5 years, Current Deferred Revenue stood at $18.7 million in 2019, then rose by 6.27% to $19.9 million in 2020, then soared by 40.18% to $27.9 million in 2021, then skyrocketed by 939.06% to $290.1 million in 2022, then plummeted by 99.55% to $1.3 million in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $1.3 million, $1.5 million, and $290.1 million for Q2 2023, Q1 2023, and Q4 2022 respectively.